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Abstract
Abnormalities of one carbon, glutathione and sulfide metabolisms have recently emerged as novel pathomechanisms in
diseases with mitochondrial dysfunction. However, the mechanisms underlying these abnormalities are not clear. Also, we
recently showed that sulfide oxidation is impaired in Coenzyme Q10 (CoQ10) deficiency. This finding leads us to hypothesize
that the therapeutic effects of CoQ10, frequently administered to patients with primary or secondary mitochondrial
dysfunction, might be due to its function as cofactor for sulfide:quinone oxidoreductase (SQOR), the first enzyme in the
sulfide oxidation pathway. Here, using biased and unbiased approaches, we show that supraphysiological levels of CoQ10
induces an increase in the expression of SQOR in skin fibroblasts from control subjects and patients with mutations in
Complex I subunits genes or CoQ biosynthetic genes. This increase of SQOR induces the downregulation of the
cystathionine β-synthase and cystathionine γ -lyase, two enzymes of the transsulfuration pathway, the subsequent
downregulation of serine biosynthesis and the adaptation of other sulfide linked pathways, such as folate cycle, nucleotides
metabolism and glutathione system. These metabolic changes are independent of the presence of sulfur aminoacids, are
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CoQ10 supplementation are mediated by the overexpression of SQOR. Our results contribute to a better understanding of
how sulfide metabolism is integrated in one carbon metabolism and may explain some of the benefits of CoQ10
supplementation observed in mitochondrial diseases.
Graphical Abstract
Introduction
Mitochondria are the primary site of cellular energy production
and can also have a broad range of other vital functions for
the cells. Dysfunction of mitochondria is observed in common
age-related disorders, including neurodegenerative diseases,
metabolic syndrome, cardiomyopathies and sarcopenia (1).
Mitochondrial dysfunction is likewise the primary characteristic
of monogenic disorders that affect one of the genes that encode
the estimated 1000 proteins identified in mitochondria (2).
Among these, mutations in genes encoding essential proteins
for the Oxidative Phosphorylation (OXPHOS) system account
for the most common group of inborn errors of metabolism,
the so-called mitochondrial diseases, which are clinically
heterogeneous and can involve any organ or tissue. This clinical
heterogeneity suggests that multiple pathogenic and adaptive
mechanisms are involved in the clinical manifestations of the
mitochondrial diseases.
Recently, the remodeling of folate cycle, and its link to
transsulfuration pathway (the hydrogen sulfide biosynthetic
pathway) and nucleotides metabolism, have been proposed
as novel mechanisms contributing to the pathophysiological
features of mitochondrial diseases, mainly those caused by
deletions or depletion of the mitochondria DNA (mtDNA) (3–
5). Also, alterations of hydrogen sulfide (H2S) metabolism are
observed after pharmacological inhibition of complex I (CI), the
first enzyme of the mitochondrial respiratory chain (6), and two
recent studies have shown that Coenzyme Q (CoQ) deficiency
severely decreases the levels of Sulfide Quinone Oxidoreductase
(SQOR), the first enzyme in the mitochondrial H2S oxidation
pathway. Thus, the decrease in SQOR leads to an impairment of
H2S oxidation, leading to accumulation of H2S and depletion on
the glutathione system (7,8). However, the regulation of these
pathways and how they interplay with each other is unknown,
and therapeutic interventions aimed to revert their alterations
have failed (3).
The heterogenous combination of all these pathomech-
anisms makes it difficult to develop effective therapeutic
interventions. Thus, the therapeutic options for mitochondrial
disorders are mostly limited to palliative care (9,10), although
promising therapeutic options are being developed for specific
diseases (11,12). In general, CoQ10 supplementation is recom-
mended for patients with mitochondrial disorders or other
diseases with secondary mitochondrial dysfunction, and clinical
improvements have been reported in some cases, but others do
not show any positive response (13). The therapeutic efficacy
of CoQ10 supplementation in the treatment of mitochondrial
disorders might be explained by the development of secondary
CoQ10 deficiency, which frequently occurs (13–16). Alternatively,
we can postulate that supraphysiological levels of CoQ10 could
induce an increase in the levels of SQOR, with consequent
modifications in the up-stream transsulfuration pathway, which
supplies H2S to the oxidation pathway.
Collectively, these data led us to hypothesize that (1) changes
in the function of the mitochondrial respiratory chain or sup-
raphysiological levels of CoQ10, might alter sulfide metabolism
through the modification of the levels and activity of SQOR,
which in turn may induce changes in other sulfide enzymes
that are metabolically connected with other metabolic path-
ways, such as, serine biosynthesis, folate cycle or nucleotides
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Figure 1. CoQ10 supplementation induces changes in pathways that are direct or indirectly related to sulfide metabolism. (A and B) Results of the pathway analysis
showing the canonical pathways most enriched in the differentially expressed gene list of the CoQ10 treated cells dataset. The pathways related to sulfide metabolism
are indicated by a brown square or a purple arrow. (A) Analysis of the control cells. (B) Analysis of the NDUFS1 mutant cells. (C) Pathways related to sulfide metabolism.
SQOR, the first enzyme in the mitochondrial hydrogen sulfide oxidation pathway, is the target of CoQ10.
sulfur aminoacids availability as a source of H2S. Thus, we have
used biased and unbiased approaches to assess how metabolic
pathways change in different models of OXPHOS disorders, how
they regulate each other, and how they are modified by CoQ10
supplementation and/or sulfur aminoacids availability.
Results
CoQ10 supplementation modifies sulfide metabolism
and the pathways associated to one carbon metabolism
We first analyzed the effect of CoQ10 supplementation in the
transcriptomic profiles of skin fibroblasts from a control subject
and a patient with Complex I deficiency due to a mutation in
the NDUFS1 gene (Supplementary Material, Table S1; Data File
S1). Both control and NDUFS1 mutant cells have similar levels
of CoQ10 and supplementation with 100 μm CoQ10 significantly
increases the cellular content of CoQ10 (Supplementary Material,
Table S2), although the majority of these CoQ10 molecules would
be located in the cell membrane and a low proportion would
enter into the mitochondria (17,18). The increase of the cell con-
tent of CoQ10 modifies a variety of canonical pathways involved
in cell metabolism, being the number of the altered pathways
higher in the treated mutant cells than in the control treated
cells (Fig. 1A and B).
About 20–35% of the canonical pathways that CoQ10 modifies
are related to sulfide metabolism or to pathways associated to
one carbon metabolism. Specifically, CoQ10 supplementation in
control cells affects the pathways of serine and glycine biosyn-
thesis, the salvage pathway of pyrimidine biosynthesis and the
pyrimidine deoxyribonucleotides de novo biosynthesis (Fig. 1A).
CoQ10 supplementation in the NDUFS1 mutant cells modifies the
tetrahydrofolate salvage from 5,10-methenyltetrahydrefolate,
folate transformation I, folate polyglutamylation, cysteine
biosynthesis/homocysteine degradation, the pathway of serine
and glycine biosynthesis, the guanosine nucleotides degradation
III, the purine nucleotides degradation II, the adenosine
nucleotides degradation II, the urate biosynthesis/inosine 5′-
phosphate degradation and the salvage pathways of pyrimidine
ribonucleotides (Fig. 1B). Importantly, all these pathways are
interconnected in the cell’s metabolism (Fig. 1C).
Further analysis of the indicated pathways shows that, in
the sulfide metabolism, CoQ10 supplementation up-regulates
SQOR (sulfide oxidation pathway) and down-regulates CSE and
CBS (transsulfuration pathway), in both control and mutant
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In the serine biosynthesis, five key genes (PHGDH, PSAT1,
PSDH, PSAT1P3 and PSAT1P4), are under-expressed after CoQ10
supplementation in both control and mutant cells (Fig. 2C and D
and Supplementary Material, Fig. S1). An unbalance in the
genes that encode mitochondrial proteins is observed in the
folate cycle, in form of a decrease in the expression of SHMT2
and MTHFD2 and an increase in the expression of MTHFD2L
after CoQ10 supplementation in both control and mutant cells
(Fig. 2E and F and Supplementary Material, Fig. S1). Additionally,
in the nucleotides’ metabolism, PRKCH, MAP2K8, MAP2K6,
DMPK, AK4 and IMPDH2 are under-expressed, while EIF2AK2,
CMPK2, APOBEC3G, APOBEC3F, APOBEC3B, AK5 and XDH are
over-expressed after CoQ10 supplementation in both control
and mutant cells (Fig. 2G and H and Supplementary Material,
Fig. S2). The direction of the fold change for some of these
genes after CoQ10 supplementation, e.g. SQOR, CSE, PSAT1P4,
PHGDH, MTHFD1, PRKCH, EIF2AK2, DMK, CMPK2, APOBEC3G,
APOBEC3F, APOBEC3B or AK4, is the opposite to the fold change
direction in the mutant cells compared with control cells
(Supplementary Material, Fig. S3). To check whether those
changes in genes expression result in a metabolic adaptation,
we also quantified the levels of serine and glycine, two
metabolites involved in one carbon metabolism that are altered
under mitochondrial dysfunction. Serine/glycine ratio slightly
decreases in fibroblasts with NDUFS1 mutation, compared with
control fibroblasts. Interestingly, serine/glycine ratio increases in
control and mutant cells (Fig. 2I). Therefore, these data indicate
that CoQ10 supplementation modifies sulfide metabolism and
associated pathways, being all on them related to mitochondrial
metabolism (Supplementary Material, Fig. S4).
CoQ10 supplementation modifies sulfide metabolism
gene expression in cells with mutations in different
Complex I or CoQ-biosynthetic genes
Among all changes described above, the upregulation of SQOR
is likely the primary effect of CoQ10 since that enzyme requires
CoQ10 for its normal activity and CoQ10 deficiency causes a
reduction in the levels of SQOR (7,8). Furthermore, SQOR needs
the supply of hydrogen sulfide produced by cystathionine β-
synthase (CBS) and cystathionine γ -lyase (CSE) in the transsul-
furation pathway (Supplementary Material, Fig. S4). Thus, we
extended the study by quantifying of the gene expression of
enzymes of the hydrogen sulfide oxidation pathway, i.e. SQOR,
thiosulfate sulfurtransferase (TST) and sulfite oxidase (SUOX),
and the transsulfuration/hydrogen sulfide production pathways,
i.e. CBS, CSE and 3-mercaptopyruvate sulfurtransferase (3MST),
in additional cells that carry mutations in different Complex I
subunits or CoQ-biosynthetic genes (Supplementary Material,
Table S1).
Those cells have different residual levels of CI activity (Sup-
plementary Material, Table S1), and we observed that the abnor-
malities in the levels of SQOR and CSE detected in the NDUFS1
mutant cells are not a common pattern in all Complex I defi-
ciency cells. Specifically, SQOR mRNA levels are 10–20% signif-
icantly reduced in NDUFS1, NUUFS3 and NDUFS8 mutant cells
compared with controls cells (Fig. 3A). TST mRNA levels are sig-
nificantly increased in NDUFS3, NUUFS8, ND3, COQ4 and PDSS2
mutant cells compared with control cells (Fig. 3B). The levels of
SOUX and CBS mRNA are similar in mutant and control cells
(Fig. 3C and D). CSE mRNA levels are significantly increased in
ND6, COQ4 and PDSS2 mutant cells compared with control cells
(Fig. 3E). 3MST mRNA levels are only significantly increased in
COQ4 mutant cells compared with control cells (Fig. 3B). There-
fore, the changes on SQOR and CSE detected in the RNAseq
analysis in the NDUFS1 cells are not a common pattern in all
Complex I deficiency cells.
CoQ10 supplementation significantly increases the cellular
content of CoQ10 in all cell lines (Supplementary Material, Table
S2). That increase in the cell content of CoQ10 induces a con-
sistent increase of SQOR mRNA levels and decrease of CBS and
CSE mRNA levels in all cells (Fig. 3A, D and E), although no gen-
eralized changes are detected on TST, SOUX or 3MST mRNA
levels (Fig. 3B, C and F). Specifically, the increase of SQOR mRNA
levels is statistically significant in controls cells and NDUFB3,
NDUFB9, NDUFS1, NDUFS8, ND3, ND6, COQ4 and PDSS2 mutant
cells (Fig. 3A); the decrease of CBS mRNA levels is statistically
significant in NDUFB3, NDUFS1, NDUFS3, NDUFS8, ND3, COQ4 and
PDSS2 mutant cells (Fig. 3D); and the decrease of CSE mRNA
levels is statistically significant in control cells and NDUFB3, ND3,
ND6, COQ4 and PDSS2 mutant cells (Fig. 3E). Also, a significant
decrease in TST mRNA levels is detected only in NDUFS3 and
COQ4 mutant cells after CoQ10 supplementation (Fig. 3B). There-
fore, we found a remarkable inverse correlation between the
mRNA levels of SQOR and the mRNA levels of CBS and CSE after
CoQ10 supplementation.
The modification of the expression of the sulfide
oxidation genes after CoQ10 supplementation correlates
with the changes in the levels of the sulfide oxidation
proteins, and is independent of sulfur aminoacids
availability
We assessed whether CoQ10 supplementation modified sulfide
enzymes protein levels, as a result of the change in their
gene expression. Moreover, since it has been reported that
sulfide metabolism can be adapted to dietary restriction in
sulfur aminoacids (SAAR) (19,20), we also evaluated whether
the availability of sulfur aminoacids affects sulfide metabolism
in CI and CoQ10 deficiency. Before CoQ10 supplementation,
the levels of SQOR were significantly lower in two (out of
three) of the cells with the lowest CI activity (NDUFB3 and
NDUFS1) and in the CoQ10 deficiency cells, compared with
controls, although the levels of SQOR were normal in the cells
with 40–60% of residual CI activity, as well as in one (out of
three) of the mutant cells with the lowest CI activity (NDUFB9)
(Fig. 4A and B; Supplementary Material, Fig. S5A and B). The
levels of TST and SUOX were similar in mutant and control
cells, except for the increased levels of TST in NDUFS3 and
COQ4 mutant cells (Fig. 4A, C and D; Supplementary Material,
Fig. S5A, C and D). All these changes were similar in the
cells cultured under SAAR (Fig. 4 and Supplementary Material,
Fig. S5; quantitative data not shown). Therefore, there was a
general correlation between mRNA and protein levels in the
mutant cells, with some exceptions. Interestingly, the levels of
SQOR are consistently increased in all cell types after CoQ10
supplementation compared with the untreated cells, being the
differences statistically significant in controls, NDUFB3, NDUFS1,
NDUFS8, ND3, COQ4 and PDSS2 mutant cells (Fig. 4A and B;
Supplementary Material, Fig. S5A and B). Moreover, the levels of
SQOR were rescued in NDUFB3, NDUFS1, COQ4 and PDSS2 mutant
cells after CoQ10 supplementation (Fig. 4A and B; Supplementary
Material, Fig. S5A and B). On the contrary, the levels of TST and
SUOX did not change after CoQ10 supplementation, except for
a partial decrease of TST levels in ND6 mutant cells after CoQ10
supplementation (Fig. 4A, C and D; Supplementary Material,
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Figure 2. Changes in gene expression of pathways related to sulfide metabolism in response to CoQ10 supplementation. (A and B) Changes in the expression of genes
related to cysteine biosynthesis and sulfide metabolism in control (A) and mutant (B) cells after CoQ10 supplementation. (C and D) Changes in the expression of genes
related to serine/glycine biosynthesis in control (C) and mutant (D) cells after CoQ10 supplementation. (E and F) Changes in the expression of genes related to the folate
cycle in control (E) and mutant (F) cells after CoQ10 supplementation. (G and H) Changes in the expression of genes related to nucleotides metabolism in control (G)
and mutant (H) cells after CoQ10 supplementation. Bars in blue indicate genes overexpressed; bars in orange indicates genes underexpressed. Dotted lines indicate the
threshold considered for overexpression (log2 FC = 0.585) or underexpression (log2 FC = −0.585). Asterisks indicates the genes that exceed the fold change threshold and
have P-values less than 0.05 in the comparison of treated and untreated cells in both control and mutant cells. C, control; CT, control treated with CoQ10; M, NDUFS1
mutant; MT, NDUFS1 mutant treated with CoQ10. (I) Serine/Glycine ratio in control (black bars) and patients’ cells (red bars) with mutations in NDUFS1 and NDUFB3,
and their response to CoQ10 supplementation (checkered bars). Data are expressed as mean ± SD. ∗∗P < 0.01; differences versus control. +P < 0.05; ++P < 0.01; control
versus control + CoQ10 or Complex I deficiency versus Complex I deficiency + CoQ10 (t-test; n = 3 for each group; n = 3 for each group).
cells cultured under SAAR (Fig. 4 and Supplementary Material,
Fig. S5; quantitative data not shown). Therefore, SQOR is the
most affected enzyme in the H2S oxidation pathway under CI
deficiency or low/high levels of CoQ10, and those changes are
not affected by SAAR.
To assess whether the effects of CoQ10 supplementation,
CI deficiency or different availability of sulfur aminoacids on
SQOR levels observed in vitro also occur in vivo, we measured
SQOR levels in three different systems: (1) in the liver of
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Figure 3. CoQ10 supplementation modifies the expression of key genes in the mitochondrial hydrogen sulfide oxidation pathway and the transsulfuration pathway.
(A–C) Expression levels of genes involved in the mitochondrial hydrogen sulfide oxidation pathway. (D–F) Expression levels of genes involved in the transsulfuration
pathway. Black bars indicate control cells; red bars indicate cells with mutation in Complex I genes; blue bars indicate cells with mutations in CoQ10 biosynthetic genes.
Solid bars indicate untreated cells; checkered bars indicate CoQ10-treated cells. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences versus
Control. +P < 0.05; ++P < 0.01; +++P < 0.001; control versus control + CoQ10 or Complex I deficiency versus Complex I deficiency + CoQ10 or CoQ10 deficiency versus
CoQ10 deficiency + CoQ10 (t-test; n = 3 for each group; n = 3 for each group). C, control; B3, NDUFB3 mutant; B9, NDUFB9 mutant; S1, NDUFS1 mutant; S3, NDUFS3 mutant;
S8, NDUFS8 mutant; ND3, ND3 mutant; ND6, ND6 mutant; COQ4, COQ4 mutant; PDSS2, PDSS2 mutant; CI Def, cells with Complex I deficiency; CoQ Def, cells with CoQ10
deficiency; Q, CoQ10.
liver is the tissue that accumulates more CoQ10 when it is orally
administrated (21,22); (2) in the brain of Ndufs4−/− mice, the
symptomatic tissue in this model of Leigh Syndrome due to
CI deficiency (23) and (3) in the kidney of Coq9R239X mice under
supplementation with N-acetylcysteine (NAC), a sulfur-containing
aminoacid, or a diet with restriction in sulfur aminoacids (SAAR),
since the kidney has a very active sulfide metabolism and it
has reduced levels of SQOR in this model of CoQ deficiency
(8,24). The levels of total CoQ (CoQ9 + CoQ10) increase in the
liver of C57BL/6J mice after 1 month of water-soluble CoQ10H2
supplementation (Supplementary Material, Table S3). Consistent
with this result, also the levels of SQOR increase in the liver
of the same treated mice, compared with the untreated mice
(Fig. 4E). The brain of Ndufs4−/− mice shows normal levels of
CoQ9, as compared with those in Ndufs4+/+ mice (Supplementary
Material, Table S3). However, the SQOR levels are significantly
increased in mitochondria from the brain of Ndufs4−/− mice,
compared with Ndufs4+/+ mice (Fig. 4F). The levels of CoQ9
and SQOR are significantly lower in the kidneys of Coq9R239X
mice than in the kidneys of Coq9+/+, and they are not rescued
by NAC or SAAR supplementation (Supplementary Material,
Table S3 and Fig. 4G). These results indicate that CoQ10 is one
of the factors that may regulate the levels of SQOR in vivo,
independently of the sulfur-aminoacids availability. Moreover,
SQOR is up-regulated, probably as a compensatory response, in
the brain of the mouse model of Leigh Syndrome due to severe CI
deficiency.
The abnormalities of SQOR levels in mitochondrial
dysfunction are independent of mitochondrial
supercomplexes formation
Since we have not identified a robust correlation between the
SQOR levels and the residual CI activity, and because SQOR
could interact with the mitochondrial supercomplexes though
one of its components, i.e. CoQ, we evaluated the mitochondrial
supercomplexes in control and mutant cells and mice. In the in
vitro experiments, we used NDUFS8, NDUFS1 and NDUFB3 mutant
cells, which have 54, 37 and 17% of residual CI activity, respec-
tively, and a decrease in SQOR levels in the two latter cases.
A decrease in the CI bound to supercomplexes is observed in
the three mutant cells compared with control cells (Supplemen-
tary Material, Fig. S6A–C), while free CI is almost undetectable
(Supplementary Material, Fig. S6A and D). Moreover, a decrease
in the CIII bounds to supercomplexes and an increase of the
free CIII are observed in the three mutant cells compared with
control cells (Supplementary Material, Fig. S6E–H). Therefore,
we did not observe a correlation between the disruption of
the mitochondrial supercomplexes and the decrease in SQOR
levels.
To test whether SQOR could be detected in association with
some mitochondrial complex/supercomplex, we performed
BNGE-Page with mitochondria from kidneys of wild-type,
Ndufs4−/− and Coq9R239X mice and incubated the membranes
with an anti-SQOR antibody. The pattern of bands is similar
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Figure 4. The levels of SQOR are modified under mitochondrial dysfunction or CoQ10 supplementation, independently of sulfur amino acids availability. (A–D) Levels
of the proteins of the mitochondrial hydrogen sulfide oxidation pathway in human skin fibroblasts from control and patients with mutations in Complex I subunits
or CoQ10 biosynthetic genes. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences versus Control. +P < 0.05; ++P < 0.01; +++P < 0.001;
Control versus Control + CoQ10 or Complex I deficiency versus Complex I deficiency + CoQ10 or CoQ10 deficiency versus CoQ10 deficiency + CoQ10 (t-test; n = 3 for
each group; n = 3 for each group). C, control; S1, NDUFS1 mutant; B3, NDUFB3 mutant; S3, NDUFS3 mutant; ND6, ND6 mutant; PDSS2, PDSS2 mutant; CI Def, cells with
Complex I deficiency; CoQ Def, cells with CoQ10 deficiency; Q, CoQ10; -SAA, medium without sulfur aminoacids. The blot image (A) has been made from three different
membranes, as follow: blot 1, control and PDSS2; blot 2, NDUFS1 and ND6; blot 3, NDUFB3. (E) Levels of SQOR in the liver of C57bl6j mice supplemented with ubiquinol-10
for 1 month. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; WT versus WT + CoQ10H2 (t-test; n = 4 for each group). (F) Levels of SQOR in the brain
of Ndufs4−/− mice. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; Ndufs4+/+ versus Ndufs4−/− (t-test; n = 5 for each group). (G) Levels of SQOR
in the kidneys of Coq9R239X with vehicle, NAC or under SAAR. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences versus Coq9+/+ (t-test;
n = 3 for each group; n = 3–5 for each group).
However, if we incubate the membrane with the anti-rabbit
secondary antibody a similar pattern of bands is obtained
(Supplementary Material, Fig. S6J), and this mainly corresponds
to CIII (Supplementary Material, Fig. S6K), indicating some kind
of cross-reaction between anti-rabbit antibody and some subunit
of the CIII. Thus, we are not able to detect SQOR associated
to any mitochondrial complex/supercomplex. Those results
correlate with the data obtained by Van Strien and colleagues
in a proteomic analysis in blue native gels run with samples of
skin fibroblasts from control subjects (25). The representation of
those data shows that the major proportion of SQOR is not bound
to respiratory complexes or supercomplexes (Supplementary
Material, Fig. S6L–N).
CoQ10 supplementation downregulates the
transsulfuration pathway, independently of sulfur
aminoacids availability
To evaluate whether the transsulfuration pathway may adapt
to the changes of SQOR levels, we quantified the levels of
CBS, CSE and 3MST in vitro in the same experimental groups
used to study the H2S oxidation pathway. The levels of CBS
are significantly increased in NDUFS3, COQ4 and PDSS2 mutant
cells (Fig. 5A and B; Supplementary Material, Fig. S7A and B).
The levels of CSE are increased in NDUFS1, NDUFS3, ND3 and
COQ4 mutant cells (Fig. 5A and C; Supplementary Material, Fig.
S7A and B). The levels of 3MST do not change in any mutant
cells compared with control cells. Therefore, CBS and CSE are
increased in certain cases of CI or CoQ deficiency.
After supplementation with CoQ10, the levels of CBS and
CSE consistently decrease in all cell lines, compared with
untreated cells (Fig. 5A–C; Supplementary Material, Fig. S7A–C),
although the decrease is statistically significantly only in
controls and NDUFB3, NDUFS3, ND3, ND6, COQ4 and PDSS2
mutant cells for CBS (Fig. 5B and Supplementary Material, Fig.
S7B); and controls and NDUFB9, NDUFS1 and PDSS2 mutant
cells for CSE (Fig. 5C and Supplementary Material, Fig. S7C).
On the contrary, the levels of 3MST are not modified after
CoQ10 supplementation (Fig. 5A and D; Supplementary Material,
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Figure 5. CoQ10 regulates the enzymes of transsulfuration pathway independently of sulfur amino acids availability. (A–D) Levels of the proteins of the transsulfuration
pathway in human skin fibroblasts from control and patients with mutations in Complex I subunits or CoQ10 biosynthetic genes. Data are expressed as mean ± SD.∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences versus Control. +P < 0.05; ++P < 0.01; +++P < 0.001; Control versus Control + CoQ10 or Complex I deficiency versus
Complex I deficiency + CoQ10 or CoQ10 deficiency versus CoQ10 deficiency + CoQ10 (t-test; n = 3 for each group; n = 3 for each group). C, control; S1, NDUFS1 mutant; B3,
NDUFB3 mutant; S3, NDUFS3 mutant; ND6, ND6 mutant; PDSS2, PDSS2 mutant; CI Def, cells with Complex I deficiency; CoQ Def, cells with CoQ10 deficiency; Q, CoQ10;
-SAA, medium without sulfur aminoacids. The blot image (A) has been made from three different membranes, as follow: blot 1, control and PDSS2; blot 2, NDUFS1 and
ND6; blot 3, NDUFB3. (E) Levels of CBS in the liver of C57bl6j mice supplemented with ubiquinol-10 for 1 month. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01;
∗∗∗P < 0.001; WT versus WT + CoQ10H2 (t-test; n = 4 for each group). (F) Levels of CBS in the brain of Ndufs4−/− mice. Data are expressed as mean ± SD. ∗P < 0.05;∗∗P < 0.01; ∗∗∗P < 0.001; Ndufs4+/+ versus Ndufs4−/− (t-test; n = 5 for each group). (G) Levels of SQOR in the kidneys of Coq9R239X with vehicle, NAC or under SAAR.
Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences versus Coq9+/+ (t-test; n = 3 for each group; n = 3–5 for each group).
cultured under SAAR (Fig. 5A and Supplementary Material, Fig.
S7A; quantitative data not shown). Therefore, there is also an
indirect correlation between the protein levels of SQOR and
the protein levels of CBS and CSE after CoQ10 supplementation.
The effect of CoQ10 over SQOR and CBS is also confirmed
with a lower concentration of CoQ10 (Supplementary Material,
Fig. S8).
In vivo, the levels of CBS are slightly decreased in the liver
of C57BL/6 J mice treated with CoQ10H2 and in the brain of
Ndufs4−/− mice, compared with the respective control animals
(Fig. 5E and F). In the kidneys of Coq9R239X mice, the levels of
CBS slightly increased compared with Coq9+/+ mice and this
change was maintained under supplementation with NAC or
SAAR (Fig. 5G). Therefore, the inverse correlation between SQOR
and CBS also occurs in vivo.
CoQ10 indirectly regulates the transsulfuration pathway
through SQOR and/or other transcriptional regulatory
pathways, and independently of oxidative stress
To assess whether CoQ10 regulates the enzymes of the transsul-
furation pathway directly or through the modulation of SQOR,
we overexpressed SQOR in control cells and NDUFB3 and
NDUFS1 mutant, and measured mRNA and protein levels of
SQOR, CBS and CSE. The transduction with SQOR-LV produces
significant increases of SQOR mRNA and protein levels in
control and mutant cell, compared with the matched non-
transduced cells (Fig. 6A, D and E). In parallel, the mRNA and
protein levels of CBS and CSE are significantly decreased in
the cells transduced with the SQOR-LV, compared with the
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Figure 6. CoQ10 indirectly regulates the transsulfuration pathway through SQOR. (A–C) Effect of genetic overexpression of SQOR in the expression levels of the genes
SQOR, CBS and CSE. (D–G) Effect of genetic overexpression of SQOR in the levels of the proteins SQOR, CBS and CSE. (H–K) Effect of genetic overexpression of SQOR in
the expression levels of the genes PSAT1, MTHFD2L, CMPK2 and EIF2AK2. C, control; B3, NDUFB3 mutant; S1, NDUFS1 mutant; NT, non-transduced; T-SQOR, lentiviral
vector containing SQOR cDNA. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences versus Control NT. +P < 0.05; ++P < 0.01; +++P < 0.001;
Control NT versus Control T-SQOR or Complex I deficiency NT versus Complex I deficiency T-SQOR or CoQ10 deficiency NT versus CoQ10 deficiency T-SQOR (t-test;
n = 3 for each group; n = 3–4 for each group).
that the effect of CoQ10 over CBS and CSE is an indirect action
through the modulation of SQOR levels. We also assessed the
effects of SQOR overexpression on serine biosynthesis, folate
cycle and nucleotides metabolism, and observed that SQOR
overexpression reproduces the gene expression profile changes
caused by CoQ10 supplementation (Fig. 6H–K). Specifically, the
expression of PSAT1 slightly decreases in both control and
NDUFS1 SQOR-transduced cells (Fig. 6H); and the expression
of MTHFFD2, CMPK2 and EIF2AK2 significantly increases in both
control and NDUFS1 SQOR-transduced cells (Fig. 6I–K).
Nevertheless, we also investigated whether the effects
of CoQ10 on the changes of the expression of the identified
genes could be attributed to a direct interaction of COQ10 with
pathways involved in transcriptional regulation or cell signaling.
Transcriptomics analysis reveals that CoQ10 partially modifies
the STAT3 (Supplementary Material, Fig. S9A, B, E, F) and the
HIF1α signaling (Supplementary Material, Fig. S9A, C, E, G)
pathways in both control (Supplementary Material, Fig. S9A–C)
and NDUFS1 mutant (Supplementary Material, Fig. S9E–G) cells.
Moreover, the sumoylation pathway is altered in control cells
treated with CoQ10 (Supplementary Material, Fig. S9A and D),
and the NRF2 response in the NDUFS1 mutant cells treated
with CoQ10 (Supplementary Material, Fig. S9A and D). Therefore,
we cannot exclude that CoQ10 supplementation effects on the
transsulfuration pathway are partially mediated by its effects on
other transcriptional regulators.
To know whether the mechanism of action of CoQ10 over
sulfide metabolism may be mediated by oxidative stress, we also
tested the effects of other antioxidants, i.e. idebenone (18), NAC
or melatonin (aMT) (26), in the levels of SQOR. Idebenone induces
a profound cell death at the same dose than CoQ10, as reported
in other studies (27). The treatments with NAC or melatonin do
not modify the levels of SQOR in control cells and mutated in
NDUFS1, NDUFB3 and PDSS2 (Supplementary Material, Fig. S10),
suggesting that oxidative stress is not involve in the regulation
of SQOR in vitro.
The levels of SQOR and CBS correlate with the levels of
total GSH in vivo
We previously reported that the glutathione system is decreased
in specific tissues of animals with CoQ deficiency, a fact that
we attributed to the disruption of the sulfide metabolism (7,8).
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Figure 7. The changes in sulfide metabolism correlate with the alterations of the glutathione system in vivo. (A–C) Total glutathione (A), GSSG/GSH ratio (B) and
glutathione enzymes levels (C) in Coq9R239X with regular chow, a diet supplemented with N-acetylcysteine (NAC) or a diet with restricted content of sulfur aminoacids
(SAAR). Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences versus Coq9+/+ (t-test; n = 3 for each group; n = 3–4 for each group). (D–F) Total
glutathione (D), GSSG/GSH ratio (E) and glutathione enzymes levels (F) in Ndufs4−/−. Data are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; differences
versus Ndufs4+/+ (t-test; n = 4 for each group).
in the kidneys of Coq9R239X treated with NAC or SAAR, as well
as in the brain of Ndufs4−/− mice. The kidneys of Coq9R239X,
which have decreased levels of SQOR and increased levels of CBS,
show decreased levels of total glutathione, and that decrease is
preserved after the supplementation with NAC or SAAR (Fig. 7A).
Moreover, the GSSG/GSH ratio is reduced in untreated Coq9R239X
mice, as well as in Coq9R239X mice treated with NAC or SAAR,
compared with Coq9+/+ mice (Fig. 7B). The levels of the glu-
tathione enzymes, GPx and GRd, are mildly decreased in the
three experimental groups of Coq9R239X mice, compared with
Coq9+/+ mice, although the decrease is statistically significant
only in the case of GPx in untreated Coq9R239X mice (Fig. 7C). The
brain of Ndufs4−/− mice, which has increased levels of SQOR
and decreased levels of CBS, shows increased levels of total
glutathione and GSSG/GSH ratio, compared with Ndufs4+/+ mice
(Fig. 7D and E), but no differences were found in the levels of
glutathione enzymes. Globally, these data confirm that sulfide
metabolism influences the levels of glutathione, independently
of the sulfur aminoacids availability.
Discussion
Mitochondrial dysfunction causes heterogeneous clinical
presentations, due to the variable involvement of multiple
metabolic pathways related to the mitochondrial metabolism,
e.g. one carbon metabolism or fatty acids oxidation (3–
5,14). Therefore, finding therapeutic approaches for those
dysfunctions is challenging. Oral CoQ10 supplementation is a
common recommended therapeutic approach in patients with
mitochondrial disorders and other diseases with secondary
mitochondrial involvement. However, its rationale use is not
well understood, particularly in patient with normal CoQ10
levels. Here, we show that supraphysiological levels of CoQ10
induce the overexpression of SQOR, the first enzyme of the
mitochondrial hydrogen sulfide oxidation pathway (sulfide
catabolization), leading to downregulation of CBS and CSE. These
two latter enzymes belong to the transsulfuration pathway
(sulfide biosynthesis), which is metabolically connected to
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metabolism (3,28). Thus, supraphysiological levels of CoQ10
result in a modulation of these pathways, restoring the function
that is altered by mitochondrial dysfunction (3–5,14).
We previously reported that CoQ deficiency causes a severe
reduction in the levels of SQOR, leading to a disruption of the
sulfide metabolism and a decrease in the glutathione levels (7,8).
In the current study, we show that CoQ deficiency also affects the
transsulfuration pathway, independently of the availability of
sulfur aminoacids. Additionally, we show that specific molecular
defects in Complex I subunits cause disruption of the sulfide
metabolism. However, those alterations do not correlate with
the residual Complex I activity and are not due to an inter-
action of the SQOR with the mitochondrial supercomplexes.
These findings suggest that the variable response of the sul-
fide metabolism to complex I deficiency could influence the
heterogenous disease phenotype (29), in part because of the
effects of that response on the metabolism of glutathione, which
requires the balanced metabolism of cysteine and glycine (28,30).
Importantly, supplementation with CoQ10 in both controls
and Complex I deficiency cells causes a consistent upregulation
of SQOR and downregulation of the transsulfuration pathway,
independently of the availability of sulfur aminoacids. This mod-
ulation of the sulfide metabolism causes a therapeutic adap-
tation of metabolic pathways that are closely connected to the
transsulfuration pathway, i.e. the serine biosynthesis, the folate
cycle and the nucleotides metabolism. These metabolic path-
ways are unbalanced in a variety of models of mitochondrial dis-
eases (3–5,14), probably due to the activation of serine catabolism
(31). Specifically, CBS, CSE, PSAT1, SHMT2 and PHGDH are upreg-
ulated after 24 h of pharmacological inhibition of Complex I in
cell culture (6); Mthfd2 is induced in the skeletal muscle, heart
and brown adipose tissue of the Deletor mice, resulting in a
remodeling of the one carbon metabolism (3,5,32); Mthfd2 and
Shmt2 are induced in the heart of five different mouse models
of mitochondrial diseases due to disruption of key genes that
regulate mtDNA gene expression, mtDNA replication or trans-
lation (14); CBS, CSE, PHGDH, PSPH and PSAT1 are induced after
pharmacologically induced mtDNA depletion in vitro, leading to
an increase in serine biosynthesis and transsulfuration (4); or
MTHFD1L, MTHFD2, PSAT1, PHGDH and SHMT2 are upregulated
in the muscle of patients with mitochondrial myopathy due to
mtDNA single or multiple deletion(s) (5). Importantly, our in vitro
analyses show that supraphysiological levels of CoQ10 can rescue
all these abnormalities, inducing the downregulation of CBS, CSE,
PHGDH, PSPH, PSAT1, MTHFD1L and MTHFD2, among others, in
both control and Complex I deficiency cells. Furthermore, the
serine/glycine ratio, which is decreased in mouse models of
secondary CoQ deficiency (14), increases after CoQ10 supplemen-
tation, most likely due to a compensation in the biosynthesis and
use of serine, together with a decrease of glycine production in
the folate cycle. These changes in the transsulfuration, serine
biosynthesis and folate cycle correlate with the increase in SQOR
and an alteration in the nucleotide metabolism. However, these
effects are not likely due to an stimulation of the OXPHOS
system, where CoQ plays a central role in the Q junction (33),
since CoQ10 is able to stimulate the mitochondrial complexes
activities in cells with CoQ10 deficiency but its effect in cells
with normal levels of CoQ10 is limited (34). Therefore, high doses
of CoQ10 supplementation may provide therapeutic benefits in
patients with mitochondrial disorders and alterations in sul-
fide metabolism, serine biosynthesis, folate cycle or nucleotide
metabolism. Moreover, the effect of CoQ10 on the upregulation
of SQOR and downregulation of CBS and CSE could reduce the
clinical consequences of the accumulation of hydrogen sulfide
and reduction in glutathione levels in patients with ethylmalonic
encephalopathy due to mutations in ETHE1 (30,35) or in patients
with Leigh Syndrome due to mutations in SQOR (36). Further-
more, the effects of CoQ10 in sulfide metabolism could benefit
patients with colon cancer, thyroid carcinomas or Chron’s dis-
ease, since the increase of transsulfuration pathway has been
identified as a key pathogenic mechanism in both cases (37–
39). However, an important limitation of the exogenous CoQ10
supplementation is the low absorption and bioavailability of
this molecule. CoQ10, orally or intraperitoneally administrated,
mainly localizes in the spleen and the liver, with a low proportion
localized in the heart, muscle and kidneys, and a very low
proportion in the brain (17,21). Therefore, effective strategies to
increase the bioavailability of CoQ10 are necessary to enhance its
therapeutic potential.
The current study also contributes to elucidate the mech-
anisms of how CoQ10 is able to induces metabolic changes at
the transcriptional level. Our data demonstrate that the over-
expression of SQOR alone, could lead to the downregulation of
the transsulfuration pathway and to the adaptation of the other
metabolic pathways. Most likely, all these changes are mediated
by the detection of the levels of the SQOR products, i.e. thiosul-
fate (SSO32−) or GSH persulfide (GSS−), as it happens with the
CstR in bacteria (40). However, homologous sensors/regulators
have not been identified in mammals yet (41). Nevertheless,
the supplementation with thiosulfate in HUVEC cells induces
a decrease in CSE levels (42). Additionally, the results of our
transcriptome analysis suggest that some other mechanisms
could mediate the adaptative response to the supraphysiological
levels of CoQ10: (1) repression of STAT3 pathway (43), and the
subsequent reduction of the binding of STAT3 into the CSE
promoter, which reduces CSE expression (44); (2) activation of
the Sumoylation that could downregulate CBS (45,46) and/or (3)
alteration of HIF1α signaling that could downregulate CBS (47).
Although further studies are needed to elucidate the detailed
mechanisms of the transcriptional regulation mediated by
CoQ10, we demonstrate that supraphysiological levels of CoQ10
induce SQOR and downregulates the transsulfuration pathway,
leading to a downregulation of serine biosynthesis and an
adaptation of the linked pathways of folate cycle and nucleotides
metabolism. All these metabolic changes could be mediated
by the CoQ10–SQOR interaction, and they could explain the
therapeutic benefits of CoQ10 supplementation in some patients
with mitochondrial disorders. They, therefore, are very likely
relevant for the treatment of mitochondrial dysfunction in other
common diseases.
Materials and Methods
Human skin fibroblasts culture and treatments
Skin fibroblasts were provided by Holger Prokisch from the Uni-
versity of Munhen. Control and mutant skin fibroblasts were
obtained from patients with mutations in different subunits of
the mitochondrial Complex I or CoQ biosynthetic genes (Sup-
plementary Material, Table S1). Fibroblasts were cultured at 37◦C
and 5% CO2 in high glucose DMEM-GlutaMAX medium supple-
mented 1% MEM non-essential amino acids, and 1% antibiotic-
s/antimycotic. Fibroblasts were treated with 100 μm CoQ10, a dose
commonly used in cell culture studies (34,48), during 7 days. A
pilot study with 20 μm CoQ10, 100 μm idebenone, 100 μm NAC or
100 μm aMT for 7 days was also performed. CoQ10 was provided
by Tishcon (USA) in a water-soluble formulation that contains
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dose was studied. CoQ10, idebenone or vehicle were dissolved
in FBS prior to addition to culture medium (10% FBS). NAC was
dissolved in phosphate buffered saline (PBS). Melatonin stock
solution was prepared in 15% propylene glycol, giving a final
concentration of propylene glycol in cell culture of 0.75%. Sulfur
aminoacids restriction was carried out by incubating for up to
24 h in DMEM lacking Met and Cys (Gibco) with 10% dialyzed
FBS.
Mice use and experimental treatment
Mice were housed in the Animal Facility of the University of
Granada under a SPF zone with lights on at 7:00 a.m. and off
at 7:00 p.m. Mice had unlimited access to water and rodent
chow. All experiments were performed according to a protocol
approved by the Institutional Animal Care and Use Committee
of the University of Granada (procedure number 9-CEEA-OH-
2013) and in accordance with the European Convention for the
Protection of Vertebrate Animals used for Experimental and
Other Scientific Purposes (CETS # 123), directive 2010/63/EU on
the protection of animals used for scientific purposes and the
Spanish law (R.D. 53/2013). Animals were randomly assigned in
experimental groups. Data were randomly collected and pro-
cessed as well.
Control C57Bl6 mice were treated with ubiquinol-10 (Q10H2),
which has better bioavailability in vivo, in the drinking water
at a dose of 240 mg/kg bw/day (21). Ubiquinol-10 was provided
by Kaneka (Japan) in a water-soluble formulation that contains
gamma cyclodextrin. A control group with vehicle at the same
dose was studied. The treatment started at 1 month of age,
and the mice were euthanized for the experimental assays at
2 months of age. Livers were extracted and frozen at −80◦C
until assayed for CoQ10 or protein quantification. Ndufs4+/+ and
Ndufs4−/− mice (MGI: 3793713), a model of Leigh syndrome due
to Complex I deficiency (23), were euthanized at 4–5 weeks of
age. Brains were extracted and frozen at –80◦C until assayed for
CoQ10 or protein quantification. To quantify SQOR in the brain,
mitochondria were freshly isolated, as previously described (8).
Coq9R239X mice (MGI: 5473628) were treated with L-NAC added to
drinking water at a concentration of 1%. Separately, mice were
treated with sulfur amino acid restriction (SAAR) diet containing
0.15% Methionine and 0% Cystine (49), compared with control
diet containing 0.6% Methionine and 0.42% Cystine.
Quantification of CoQ10 levels in cells and mouse
tissues and measurement of Complex I activity
CoQ9 and CoQ10 levels were determined via reversed phase HPLC
coupled to electrochemical (EC) detection (18,50). The results
were expressed in ng CoQ/mg prot. Complex I activity was
determined as previously described (51), normalized by citrate
synthase activity, and represented as the percentage of the
control values.
Serine and glycine quantification
Serine and glycine were quantified as described (52). Cell pellets
were stored at −80◦C and extracted immediately before analysis
in ice-cold lysis/extraction buffer (methanol:acetonitrile:water
5:3:2 v/v). Samples were concentrated in a speedvac system and
the resulting dry residues were resuspended in water. Standards
of serine and glycine were dissolved in water at a concen-
tration of 10, 100 and 10 000 ng/ml. Samples were separated
through a 5 min isocratic elution on a Kinetex XB-C18 column
(150 × 2.1 mm i.d., 1.7 μm particle size—Phenomenex, Torrance,
CA, USA) at 250 μl/min (mobile phase: 5% acetonitrile, 95% 18 mΩ
H2O, 0.1% formic acid; column temperature: 25◦C). The UHPLC
system was coupled online with a Q Exactive Focus mass spec-
trometer (Thermo, San Jose, CA, USA), scanning in Full MS mode
(2 μscans) at 70 000 resolution from 60 to 200 m/z. Calibration
was performed before each analysis using a positive calibration
mix (Piercenet—Thermo Fisher, Rockford, IL, USA). Data were
analyzed using Tracefinder 4.1 software (Thermo, San Jose, CA,
USA). Analyte retention times were confirmed by comparison
with external standard retention times.
Transcriptome analysis by RNA-Seq
The RNeasy Lipid Tissue Mini Kit (Qiagen) was used to extract
total RNAs from the brainstem of five animals in each experi-
mental group. The RNAs were precipitated and their quality and
quantity assessed using Agilent Bioanalyzer 2100 and an RNA
6000 chip (Agilent Technologies). The cDNA libraries were then
constructed using the TruSeq RNA Sample Prep Kit v2 (Illumina,
Inc.) and their quality checked using Agilent Bioanalyzer 2100
and DNA 1000 chip (Agilent Technologies). The libraries were
Paired End sequenced in a HiSeq 4000 system (Illumina, Inc.).
We aimed for 4–5 Giga Bases outcome per sample. The quality of
the resulting sequencing reads was assessed using FastQC. The
Homo sapiens hg38 fasta and gtf files of the reference genome
were downloaded from the Ensembl database and indexed using
the bwtsw option of BWA (53). BWA, combined with xa2multi.pl
and SAMtools (54), was also used for aligning the sequencing
reads against the reference genome, and HTSeq was used for
counting the number of reads aligned to each genomic locus (55).
The alignments and counting were carried out in our local server
following the protocols as described (56).
After elimination of the genomic loci that aligned to <5 reads
in <5 samples and normalization of the read counts by library
size, the differential gene expression was detected using the
Generalized Linear Model (glmLRT option) statistic in EdgeR. We
used a 0.05 P-level threshold. Annotation of the differentially
expressed genes was obtained from H. sapiens hg38 genome.
The genes that passed the inclusion criteria were then sub-
jected to gene classification, using a database of hand-curated
literature on specific protein–protein interactions and regulatory
networks (Ingenuity Pathway Analysis (IPA); Ingenuity Systems,
Redwood City, CA, USA). The canonical pathways involved in
the metabolism and transcriptional regulation where the sig-
nificantly changed transcripts are involved were detected by
Ingenuity Pathway Analysis were evaluated and P-values < 0.05
were considered significant. Further, specific functional net-
works, based on published knowledge on protein–protein inter-
actions and regulatory networks, were constructed by Ingenuity
Pathway Analysis (57).
Gene expression analyses
Total cellular RNA from frozen cell pellets were extracted
and electrophoresed in 1.5% agarose gels in order to check
the RNA integrity. RNA from skin fibroblasts was extracted
using Real Total RNA Spin Plus Kit (Real). Total RNA was
quantified by optical density at 260/280 nm and was used
to generate cDNA with High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). Amplification of human
genes SQOR (Hs01126963_m1), CBS (Hs01598251_m1), CSE
(Hs00542284_m1), TST (Hs00361812_m1), SUOX (Hs00166578_m1),
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(Hs01013364_m1), EIF2AK2 (Hs00169345_m) and the human
GADPH probe, as a standard loading control (Hs99999905_m1),
was performed using quantitative real-time PCR, specific
Taqman probes (from Applied Biosystems) and the standard
curve method.
Sample preparation and western blot analysis in
tissues and fibroblasts
For western blot analyses, a glass-Teflon homogenizer was
used to homogenize mouse liver, brain and kidney samples at
1100 rpm in T-PER
®
buffer (Thermo Scientific) with protease
inhibitor cocktail (Pierce). Homogenates were sonicated and
centrifuged at 1000g for 5 min at 4◦C, and the resultant
supernatants were used for western blot analysis. For western
blot analyses in cerebral mitochondria, the pellets containing
the mitochondrial fraction were re-suspended in RIPA buffer
with protease inhibitor cocktail (8). Mitochondrial isolation
was performed as previously described (8). For western blot
analyses in skin fibroblasts, the pellets containing the cells
were re-suspended in RIPA buffer with protease inhibitor
cocktail. About 30 μg of protein from the sample extracts was
electrophoresed in 12% Mini-PROTEAN TGX™ precast gels (Bio-
Rad) using the electrophoresis system mini-PROTEAN Tetra
Cell (Bio-Rad). Proteins were transferred onto PVDF 0.45-μm
membranes using a Trans-blot Cell (Bio-Rad) and probed with
target antibodies. Protein–antibody interactions were detected
using peroxidase-conjugated horse anti-mouse, anti-rabbit or
anti-goat IgG antibodies and Amersham ECL™ Prime Western
Blotting Detection Reagent (GE Healthcare, Buckinghamshire,
UK). Band quantification was carried out using an Image Station
2000R (Kodak, Spain) and a Kodak 1D 3.6 software. Protein band
intensity was normalized to VDAC1 (mitochondrial proteins),
and the data were expressed in terms of percent relative to
wild-type mice or control cells (8,58).
The following primary antibodies were used: anti-SQRDL
(Proteintech, 17256-1-AP), anti-CBS (Proteintech, 14787-1-AP),
anti-CSE (Proteintech, 12217-1-AP), anti-TST (Proteintech, 16311-
1-AP), anti-ETHE1 (Sigma, HPA029029), anti-SUOX (Proteintech,
15075-1-AP), anti-3-MPST (Sigma, HPA001240), anti-GPx (Abcam,
ab125066), anti-GRd (Santa Cruz Biotechnology, sc-32886) and
anti-VDAC1 (Abcam, ab14734).
Evaluation of supercomplex formation by BNGE. Blue native gel
electrophoresis (BNGE) was performed on crude mitochondrial
fractions from mice kidneys or human fibroblasts. Mitochondrial
isolation from kidneys was performed as previously described
(59). One aliquot of the crude mitochondrial fraction was used
for protein determination. The remaining samples were then
centrifuged at 13 000g for 3 min at 4◦C. The mitochondrial pel-
lets were suspended in an appropriate volume of medium C
(1 M aminocaproic acid, 50 mm Bis-Tris–HCl [pH 7.0]) to cre-
ate a protein concentration of 10 mg/ml, and the membrane
proteins were solubilized in digitonin (4 g/g) and incubated for
10 min in ice. After centrifugation for 30 min at 13 000g (4◦C), the
supernatants were collected and 3 μl of 5% Brilliant Blue G dye,
prepared in 1 M aminocaproic acid, was added.
Approximately, 2 × 106 cells were used for mitochondrial iso-
lation in human skin fibroblasts. Cell pellets were resuspended
in PBS, then digitonin was added at a concentration of 8 mg/ml
and the mixture incubated for 10 min in ice for solubilizing cell
membranes. The samples were centrifuged for 5 min at 10 000g
(4◦C) and resuspended in PBS, then centrifuged for a second
time at the same conditions. The pellets were resuspended in
mitochondrial cell buffer (1.5 M aminocaproic acid, 50 mm Bis-
Tris–HCl [pH 7.0]). Then, the mitochondrial membrane proteins
were solubilized with digitonin at a final concentration of 1%
and incubated for 5 min in ice. Samples were centrifuged for
30 min at 18 000g (4◦C). The supernatants were combined with
5% Brilliant Blue G dye, prepared in 1 M aminocaproic acid.
Mitochondrial proteins were then loaded and run on a 4–
16% gradient native gel (Thermo Scientific, BN1002BOX) as
previously described (60). After electrophoresis, the complexes
were electroblotted onto PVDF membranes and sequentially
tested with specific antibodies against CI, anti-NDUFA9 (Abcam,
ab14713), CIII, anti-ubiquinol-cytochrome c reductase core
protein I (Abcam, ab110252), anti-SQRDL (Proteintech, 17256-1-
AP), anti-Vdac1 (Abcam, ab14734) and anti-rabbit (Thermofisher,
31460).
Lentiviral vectors constructs, vector production and cell
transduction
The CSQORWP LV plasmid was constructed by standard cloning
techniques using PstI/BamHI restriction enzymes to replace the
eGFP in the CEWP backbone by the SQOR cDNA (obtained by gene
synthesis from Genscript).
Vector production was performed by fast growing 293T
cells plated on amine-coated petri dishes (Sarsted, Newton,
NC) in order to achieve 80–90% confluence for transfection.
293T cells were cotransfected with the vector (CSQORWP), the
packaging (pCMVR8.91) and the envelope (pMD2.G) plasmids
using LipoD293 (SignaGen, Gainthersburg, MD, USA). Viral
supernatants were collected 48 h after transfection and the
particles were frozen or concentrated by ultrafiltration at 2000 g
and 4◦C, using 100 kDa centrifugal filter devices (Amicon Ultra-
15, Millipore, Billerica, MA). LV particles were used to transduce
skin fibroblasts by adding different volumes to the cell cultures
in order to achieve the desired multiplicities of infection. The
medium was changed after 5 h of incubation.
Glutathione measurement
Glutathione measurements were performed in total homogenate
of mouse tissues. Tissues were homogenized in sodium phos-
phate buffer (A) (100 mm sodium phosphate, 5 mm EDTA-Na2,
pH 8.0) and deproteinized using ice-cold TCA 40% and cen-
trifuged at 20 000g for 15 min. For GSH measurement, the super-
natant was incubated with a solution of (A) and orthophthalalde-
hyde/ethanol (B) (1 mg/ml) for 15 min at room temperature. The
fluorescence of the samples was measured at 340 nm excitation
and 420 nm emission wavelengths in a spectrofluorometer
plate reader (Bio-Tek Instruments Inc., Winooski, VT, USA).
For GSSG measurement, the supernatant was preincubated
with N-ethylmaleimide solution (5 mg/ml) for 40 min then
alkalinized with 0.1 N NaOH (C). Aliquots of these mixtures
were incubated with (B) and (C) for 15 min at room temperature.
Finally, the fluorescence was measured as before. GSH and GSSG
concentrations were calculated according to standard curves
that we previously prepared, and the levels of GSH and GSSG
were expressed in nmol/mg protein (8).
Statistical analysis
All statistical analyses were performed using the Prism 6 sci-
entific software. Data are expressed as the mean ± SD of 37
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compare the differences between CoQ10-treated and untreated
cells with the same genotype, as well as to compare the dif-
ferences between mutated and control cells/mice. A P-value of
0.05 or less was considered to be statistically significant. The
statistical test used for the transcriptomics analyses is described
in its respective section.
Supplementary Material
Supplementary Material is available at HMG online.
Data Availability
RNA-Seq data were generated as described above. The files have
been uploaded to the SRA repository of the National Center
for Biotechnology Information. Accession: PRJNA636102; https://
www.ncbi.nlm.nih.gov/bioproject/PRJNA636102/.
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